GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (NAS:CERE) » Definitions » FCF Yield %

Cerevel Therapeutics Holdings (Cerevel Therapeutics Holdings) FCF Yield % : -4.49 (As of Apr. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Cerevel Therapeutics Holdings FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Cerevel Therapeutics Holdings's Trailing 12-Month Free Cash Flow is $-346.11 Mil, and Market Cap is $7,711.55 Mil. Therefore, Cerevel Therapeutics Holdings's FCF Yield % for today is -4.49%.

The historical rank and industry rank for Cerevel Therapeutics Holdings's FCF Yield % or its related term are showing as below:

CERE' s FCF Yield % Range Over the Past 10 Years
Min: -8.65   Med: 0   Max: 0
Current: -4.49


CERE's FCF Yield % is ranked better than
72.97% of 1550 companies
in the Biotechnology industry
Industry Median: -15.535 vs CERE: -4.49

Cerevel Therapeutics Holdings's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.


Cerevel Therapeutics Holdings FCF Yield % Historical Data

The historical data trend for Cerevel Therapeutics Holdings's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerevel Therapeutics Holdings FCF Yield % Chart

Cerevel Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
- -6.49 -3.95 -6.02 -4.50

Cerevel Therapeutics Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.13 -9.97 -6.35 -8.51 -5.11

Competitive Comparison of Cerevel Therapeutics Holdings's FCF Yield %

For the Biotechnology subindustry, Cerevel Therapeutics Holdings's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cerevel Therapeutics Holdings's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cerevel Therapeutics Holdings's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Cerevel Therapeutics Holdings's FCF Yield % falls into.



Cerevel Therapeutics Holdings FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Cerevel Therapeutics Holdings's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-346.109 / 7689.7488
=-4.50%

Cerevel Therapeutics Holdings's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-98.322 * 4 / 7689.7488
=-5.11%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cerevel Therapeutics Holdings FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Cerevel Therapeutics Holdings FCF Yield % Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cerevel Therapeutics Holdings (Cerevel Therapeutics Holdings) Business Description

Traded in Other Exchanges
Address
222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
Executives
N Anthony Coles director, officer: See Remarks MORRIS CORP. CENTER I; BLDG. B; 4TH FLR., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Ramiro Sanchez officer: Chief Medical Officer C/O CEREVELL THERAPEUTICS HOLDINGS INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Kenneth Dipietro officer: Chief Human Resources Officer C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
Susan Altschuller officer: Chief Financial Officer 45 TENNYSON ST., SOMERVILLE MA 02145
Mark Bodenrader officer: See Remarks C/O CEREVEL THERAPEUTICS HOLDINGS INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Kathleen Tregoning officer: See Remarks C/O CEREVEL THERAPEUTICS HOLDINGS, INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Scott Akamine officer: Chief Legal Officer C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BLVD., SUITE 260, NEWPORT BEACH CA 92660
Deval L Patrick director BAIN CAPITAL, LLC, 200 CLARENDON STREET, BOSTON MA 02116
Adam Koppel director C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Perceptive Life Sciences Master Fund Ltd director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Christopher R Gordon director C/O BAIN CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Investors Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Paul D. Burgess officer: See Remarks C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Renaud Ronald C Jr director, officer: President & CEO C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Marijn E Dekkers director GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210